Abstract
This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use. Also treatment sequences for the first, second and third therapy line were analyzed. This analysis includes 958 patients with HR positive, HER2 negative MBC. 42.7% were treated with a chemotherapy in the first therapy line compared to 45.9% receiving an ET. A total of 25.9% were treated with everolimus plus anti-hormone therapy in any therapy line. 34.1% were treated with fulvestrant as single agent therapy. Analyzing therapy sequences, the administration of three different chemotherapies in a row was the most frequently used pattern. This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients. Education about the eff...Continue Reading
Citations
Dec 7, 2018·Current Opinion in Obstetrics & Gynecology·Malgorzata Banys-PaluchowskiPeter Paluchowski
Mar 17, 2020·The Oncologist·Ami N ShahMassimo Cristofanilli
Dec 24, 2018·Cancers·Michael P LuxSara Y Brucker
Feb 12, 2020·Pilot and Feasibility Studies·Stephanie StanglAchim Wöckel
Apr 8, 2020·BMC Cancer·Thomas DeckerKarin Potthoff
Oct 22, 2020·Cancers·Laura L MichelTanja N Fehm
Jun 10, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aditya Bardia, Sara Hurvitz
Dec 29, 2020·The Breast : Official Journal of the European Society of Mastology·Eduard VrdoljakFatima Cardoso
Nov 11, 2020·Cancers·Soohyeon LeeYeon Hee Park
Nov 12, 2020·Geburtshilfe und Frauenheilkunde·Elena LaakmannAndreas D Hartkopf
Nov 13, 2020·BMC Cancer·Hanna HuebnerJohannes Ettl
Nov 12, 2020·Geburtshilfe und Frauenheilkunde·Hans TeschWolfgang Janni
Mar 2, 2021·Frontiers in Oncology·Yun WuBinghe Xu
Mar 30, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter A FaschingFergus J Couch
May 28, 2021·JCO Clinical Cancer Informatics·Jennifer L Caswell-JinAllison W Kurian
Jul 27, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander HeinHans-Christian Kolberg
Apr 2, 2020·Breast Care·Christoph ThomssenKatja Ziegler-Löhr
May 20, 2021·Breast Care·Diana LüftnerPeter A Fasching